Product
131-I Apamistamab
1 clinical trial
11 indications
Indication
B-cell acute lymphoblastic leukemiaIndication
Diffuse Large B-Cell LymphomaIndication
B acute lymphoblastic leukemiaIndication
DLBCL with CIIndication
DLBCL UnclassifiableIndication
Noonan syndromeIndication
Diffuse Large B-cell LymphomaIndication
HGBLIndication
NOSClinical trial
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2025-01-01